# A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

> **NCT00361504** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 1123 (actual)

## Conditions studied

- Osteoarthritis, Hip
- Osteoarthritis, Knee
- Lower Back Pain
- Pain

## Interventions

- **DRUG:** Oxycodone CR
- **DRUG:** Tapentadol (CG5503) ER

## Key facts

- **NCT ID:** NCT00361504
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 1123 (ACTUAL)
- **Last updated:** 2014-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00361504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00361504, "A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00361504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*